State of Wisconsin Investment Board decreased its position in Teleflex Inc. (NYSE:TFX) by 1.8% during the third quarter, Holdings Channel reports. The fund owned 27,951 shares of the medical technology company’s stock after selling 500 shares during the period. State of Wisconsin Investment Board owned approximately 0.06% of Teleflex worth $4,697,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new stake in shares of Teleflex during the second quarter worth $118,000. Huntington National Bank increased its stake in shares of Teleflex by 6.5% in the second quarter. Huntington National Bank now owns 820 shares of the medical technology company’s stock worth $145,000 after buying an additional 50 shares during the last quarter. Checchi Capital Advisers LLC increased its stake in shares of Teleflex by 0.8% in the second quarter. Checchi Capital Advisers LLC now owns 837 shares of the medical technology company’s stock worth $148,000 after buying an additional 7 shares during the last quarter. Welch & Forbes LLC bought a new stake in shares of Teleflex during the second quarter worth $204,000. Finally, Broderick Brian C bought a new stake in shares of Teleflex during the second quarter worth $207,000. 94.49% of the stock is currently owned by institutional investors and hedge funds.
Teleflex Inc. (NYSE:TFX) traded up 1.25% during mid-day trading on Friday, reaching $153.19. The company had a trading volume of 214,848 shares. The firm’s 50 day moving average price is $154.04 and its 200-day moving average price is $169.28. Teleflex Inc. has a 12 month low of $125.28 and a 12 month high of $188.79. The company has a market capitalization of $6.75 billion, a price-to-earnings ratio of 26.46 and a beta of 0.88.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, October 27th. The medical technology company reported $1.80 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.02. Teleflex had a return on equity of 15.66% and a net margin of 15.09%. The firm earned $455.60 million during the quarter, compared to analysts’ expectations of $461.80 million. During the same period in the previous year, the firm posted $1.60 EPS. Teleflex’s revenue for the quarter was up 2.7% on a year-over-year basis. Equities research analysts anticipate that Teleflex Inc. will post $7.30 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 15th. Stockholders of record on Tuesday, November 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $1.36 annualized dividend and a dividend yield of 0.89%. Teleflex’s dividend payout ratio is currently 23.49%.
A number of equities research analysts have commented on the company. Zacks Investment Research cut Teleflex from a “hold” rating to a “sell” rating in a research note on Tuesday, November 1st. Stephens cut Teleflex from an “overweight” rating to an “equal weight” rating in a research note on Friday, October 28th. Leerink Swann increased their price target on Teleflex from $183.00 to $190.00 and gave the company a “market perform” rating in a research note on Friday, July 29th. Jefferies Group increased their price target on Teleflex from $157.00 to $185.00 and gave the company a “hold” rating in a research note on Friday, July 29th. Finally, Barclays PLC increased their price target on Teleflex from $183.00 to $185.00 and gave the company an “overweight” rating in a research note on Friday, July 29th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $171.33.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors.